Antidepressant Vortioxetine Shows Potential Against Aggressive Brain Tumor, New Study Reveals

Glioblastoma, a rare and aggressive brain cancer, has historically resisted effective treatments, leaving patients with few options and a bleak outlook. Emerging research, however, points to an intriguing possibility: vortioxetine, a drug primarily used to manage depression, may offer new hope in tackling this formidable disease.

At ETH Zurich, molecular biologist Sohyon Lee and her team investigated the effectiveness of existing pharmaceuticals against glioblastoma by studying human tumor tissues and conducting experiments with mice. Their results, documented in Nature Medicine, indicate that vortioxetine can markedly slow the progression of glioblastoma cells.

University Hospital Zurich neurologist Dr. Michael Weller highlights the significance of these findings: “Vortioxetine’s safety profile and affordability make it an attractive candidate. Since it’s already approved for clinical use, it could be integrated into glioblastoma treatment protocols relatively quickly, potentially improving patient outcomes.”

Add Cosmo Herald as a Preferred Source

Overcoming treatment hurdles in brain cancer

Treating brain tumors is notoriously complicated due to the blood-brain barrier, which restricts many drugs from effectively reaching the malignant cells. Vortioxetine’s ability to penetrate this barrier paves the way for new therapeutic strategies to combat glioblastoma more effectively.

The research involved screening 132 different drugs on tumor cultures derived from 27 patients, generating over 2,500 drug response profiles. Notably, some antidepressants—vortioxetine in particular—demonstrated efficacy in stalling tumor cell growth by triggering signaling pathways that prevent cancer cell division.

Advanced computer models suggested that coordinated activation between neural and cancer cells was necessary to halt tumor growth, clarifying why only certain antidepressants showed promise. This insight could guide future development of targeted glioblastoma therapies.

Encouraging evidence from animal studies

The team further tested vortioxetine's effects on mice with glioblastoma, dividing them into three experimental cohorts:

No treatment (control)
Treatment with citalopram, a commonly prescribed SSRI
Treatment with vortioxetine

Following 38 days, MRI scanning revealed that tumors in the vortioxetine group were significantly smaller and less invasive compared to both the untreated and citalopram groups. Subsequent comparative studies showed that mice treated with vortioxetine had 20-30% greater survival rates than those receiving chemotherapy alone.

Treatment GroupTumor GrowthSurvival Rate IncreaseControlHighN/ACitalopramHighMinimalVortioxetineLow20-30%

Next steps: clinical evaluation and cautious hope

Despite the promising preclinical data, experts urge restraint. Dr. Weller stresses the importance of controlled clinical trials to confirm vortioxetine’s safety and effectiveness in glioblastoma patients and to determine optimal dosing. He cautions strongly against self-treatment due to potential health risks.

This discovery offers renewed optimism for the roughly 250,000 new glioblastoma cases diagnosed globally each year. Molecular biologist Berend Snijder from ETH Zurich remarks, “Starting from this formidable tumor, we have pinpointed existing drugs that can counteract it, uncovered their mechanisms, and are preparing to evaluate their use directly with patients.”

This study underscores the value of repurposing approved medications and highlights the ongoing need for innovative cancer research. As further clinical trials proceed, this work exemplifies the unexpected pathways that can lead to transformative progress in medical science today.